Back

Long-term symptoms after SARS-CoV-2 infection in school children: population-based cohort with 6-months follow-up. Short Report

Radtke, T.; Ulyte, A.; Puhan, M. A.; Kriemler, S.

2021-05-18 epidemiology
10.1101/2021.05.16.21257255
Show abstract

Although long COVID in children exists, it is still unclear to what extent children are affected. The Ciao Corona study is a longitudinal cohort investigating SARS-CoV-2 seroprevalence and clustering of cases among around 2500 children and adolescents (hereafter referred to as children) from 55 randomly selected primary and secondary schools in the canton of Zurich in Switzerland. Between June 2020 and April 2021, we completed three testing phases where we collected venous blood for serological analysis and asked about symptoms with online questionnaires. We compared children who tested positive for SARS-CoV-2 antibodies in October/November 2020 with those who tested negative. Children who were seronegative in October/November 2020 and seroconverted or were not retested in March/April 2021 were excluded from the analysis (n=256). In March-May 2021 we assessed the presence of symptoms occurring since October 2020, lasting for at least 4 weeks, and persisting for either >4 weeks or >12 weeks. Overall, 1355 of 2503 children with a serology result in October/November 2020 and follow up questionnaire in March-May 2021 were included. Among seropositive and seronegative 6-to 16-year-old children, 9% versus 10% reported at least one symptom beyond 4 weeks, and 4% versus 2% at least one symptom beyond 12 weeks. None of the seropositive children reported hospitalization after October 2020. This study suggests a low prevalence of symptoms compatible with long COVID in a randomly selected population-based cohort of children followed over 6 months after serological testing.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 3%
13.9%
2
Eurosurveillance
based on 77 papers
Top 0.2%
13.1%
3
BMJ
based on 49 papers
Top 0.6%
5.6%
4
Swiss Medical Weekly
based on 12 papers
Top 0.1%
5.6%
5
BMJ Open
based on 553 papers
Top 22%
4.9%
6
Clinical Infectious Diseases
based on 219 papers
Top 8%
3.1%
7
Epidemiology and Infection
based on 80 papers
Top 2%
3.1%
8
The Lancet Infectious Diseases
based on 57 papers
Top 2%
2.9%
50% of probability mass above
9
Frontiers in Pediatrics
based on 24 papers
Top 1%
2.6%
10
Pediatric Pulmonology
based on 14 papers
Top 0.6%
2.4%
11
PLOS ONE
based on 1737 papers
Top 84%
2.4%
12
International Journal of Epidemiology
based on 65 papers
Top 4%
2.4%
13
BMC Medicine
based on 155 papers
Top 12%
1.7%
14
Pediatric Infectious Disease Journal
based on 16 papers
Top 1%
1.7%
15
Journal of Infection
based on 64 papers
Top 3%
1.7%
16
Science
based on 46 papers
Top 4%
1.4%
17
The Journal of Infectious Diseases
based on 137 papers
Top 7%
1.4%
18
Scientific Reports
based on 701 papers
Top 76%
1.4%
19
JAMA
based on 17 papers
Top 0.5%
1.4%
20
The Lancet
based on 16 papers
Top 0.4%
1.3%
21
International Journal of Public Health
based on 17 papers
Top 1%
1.3%
22
International Journal of Infectious Diseases
based on 115 papers
Top 16%
0.8%
23
The Lancet Regional Health - Europe
based on 32 papers
Top 1%
0.8%
24
New England Journal of Medicine
based on 49 papers
Top 3%
0.8%
25
Emerging Infectious Diseases
based on 84 papers
Top 10%
0.8%
26
ERJ Open Research
based on 36 papers
Top 3%
0.8%
27
JAMA Network Open
based on 125 papers
Top 17%
0.8%